Asset profile

Resmetirom · Rezdiffra

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — MASH / NASH

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Atherosclerotic Cardiovascular Disease · Phase 2

How the evidence outlook works ↗

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
December 2026 (1)
Phase 3MASH / NASHActive not recruiting
Est. primary completion 2026-12 · NCT05500222 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (2)
March 2027 (1)
Phase 3MASH / NASHActive not recruiting
Est. primary completion 2027-03 · NCT04951219 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)
Phase 2MASH / NASHRecruiting
Est. primary completion 2027-10 · NCT07143968 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (2)
January 2028 (1)
Phase 3MASH / NASHActive not recruiting
Est. primary completion 2028-01 · NCT03900429 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)
Phase 2MASH / NASHRecruiting
Est. primary completion 2028-08 · NCT07335601 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
July 2029 (1)
Phase 2MASH / NASHNot yet recruiting
Est. primary completion 2029-07 · NCT07763015 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.